TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells 11,337 Shares of Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

TG Therapeutics Trading Up 2.8 %

Shares of TGTX stock opened at $28.77 on Thursday. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84. The company has a market cap of $4.48 billion, a PE ratio of -287.67 and a beta of 2.24. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The business’s 50 day moving average is $31.37 and its two-hundred day moving average is $25.25.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.73 earnings per share. Equities analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the subject of a number of research reports. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. HC Wainwright increased their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. Finally, The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Hedge Funds Weigh In On TG Therapeutics

Several large investors have recently made changes to their positions in TGTX. State Street Corp grew its holdings in TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of TG Therapeutics in the second quarter worth $36,501,000. Hood River Capital Management LLC increased its position in TG Therapeutics by 6.7% during the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock worth $27,982,000 after acquiring an additional 98,892 shares during the period. Charles Schwab Investment Management Inc. raised its stake in TG Therapeutics by 0.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock valued at $27,708,000 after purchasing an additional 7,939 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.